Every 10-Q that Veracyte, Inc. (VCYT) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow VCYT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VCYT filings page.
Veracyte reported strong Q2 2026 results, with total revenue rising 15% to $150.3 million, driven by 19% growth in testing revenue to $145.7 million as diagnostic test volume increased 14% to 48,389. Biopharmaceutical and other revenue declined after exiting French contract services.
Gross profit increased to $108.5 million from $89.8 million, and the company generated net income of $25.5 million (diluted EPS $0.31) versus a small loss a year earlier. For the first half of 2026, revenue grew 18% to $289.4 million and net income reached $54.2 million.
Cash, cash equivalents and short-term investments totaled $485.2 million at June 30, 2026, supported by $81.0 million of operating cash flow. Management is increasing research and development spending, especially on the TrueMRD platform and IVD expansion, while noting macroeconomic and reimbursement risks.
Veracyte reported a strong first quarter of 2026, returning solid growth and profitability. Total revenue rose to $139.1 million from $114.5 million a year earlier, driven mainly by a 26% increase in testing revenue to $135.1 million as diagnostic test volume grew 19% to 45,248.
Net income increased to $28.7 million from $7.0 million, with basic EPS rising to $0.36 from $0.09, helped by higher gross profit and lower general and administrative expense. Operating cash flow improved to $35.2 million, and cash, cash equivalents and short-term investments totaled $439.1 million, supporting ongoing investment in R&D and new cancer diagnostic offerings.
Veracyte, Inc. reported stronger Q3 2025 results, with total revenue of $131.9 million, up from $115.9 million a year ago. Testing revenue rose to $127.8 million, while product revenue was $3.3 million and biopharmaceutical and other revenue was $0.8 million. Gross profit increased to $91.3 million. Net income was $19.1 million versus $15.2 million last year, and diluted EPS was $0.24 versus $0.19.
Operating expenses were $68.3 million. Other income (loss), net was a loss of $4.1 million, reflecting a $6.7 million loss on deconsolidation of the French subsidiary in August 2025. For the nine months, operating cash flow was $83.7 million, up from $50.6 million. The balance sheet showed cash and cash equivalents of $315.6 million, short‑term investments of $50.9 million, and stockholders’ equity of $1.26 billion as of September 30, 2025. Medicare and UnitedHealthcare represented 33% and 14% of Q3 revenue, respectively. Shares outstanding were 79,049,173 as of October 31, 2025.